M2 Pharma - Therapy Areas

Aditxt acquires Ignite Proteomics to enhance cancer therapy selection

13 March 2026 - Aditxt Inc (NASDAQ:ADTX), a social innovation platform accelerating promising health innovations, announced on Friday that it has acquired Ignite Proteomics, a commercial-stage precisi...

NASA awards Redwire USD4m to advance drug development in microgravity

11 March 2026 - Space and defence tech company Redwire Corporation (NYSE:RDW) announced on Wednesday that NASA has granted an additional USD4m to support drug development studies aboard the Internatio...

Elicera Therapeutics receives Japanese patent allowance for ELC-401 CAR T-cell candidate

11 March 2026 - Swedish clinical stage cell and gene therapy company Elicera Therapeutics AB (STO:ELIC) announced on Wednesday that the Japan Patent Office has issued a Notice of Allowance for its pat...

Curatis and Neupharma partner to develop corticorelin for peritumoral brain edema in Japan

11 March 2026 - Drug company Curatis Holding AG and Japanese pharmaceutical company Neupharma Co, Ltd announced on Wednesday that they have signed an exclusive licensing and development agreement to c...

Citius Oncology reports positive topline results from Phase 1 clinical trial of LYMPHIR combination

11 March 2026 - Oncology-focused biopharmaceutical company Citius Oncology Inc (Nasdaq:CTOR), a majority-owned subsidiary of Citius Pharmaceuticals Inc (Nasdaq:CTXR), on Tuesday reported positive topl...

GenomOncology partners with WeTrials to support CNS cancer clinical trials

11 March 2026 - Precision medicine software company GenomOncology announced on Tuesday that it has partnered with WeTrials, an AI-powered patient engagement and trial enablement platform, to help cent...